The invention provides a fusion protein of a human epidermal growth factor and metallothionein, which comprises a first part and a second part, wherein the first part is the human epidermal growth factor, the second part is the human metallothionein, and the human metallothionein is positioned at the C terminal of the human epidermal growth factor. The invention further provides an application of the fusion protein in the preparation of drugs for treating burns or scalds or wounds or ulcers and the application of the fusion protein in the preparation of skin nursing drugs. Compared with the original human epidermal growth factor and the metallothionein, the fusion protein can increase the stability, reduce the clearance rate, reduce the degradation, bring benefits and convenience to the use of the EGF-MT fusion protein and further reduce the using dosage and the medication frequency. Simultaneously, the formed fusion protein is a bifunctional molecule which has double effects of EGF and MT.